Catalyst Biosciences Inc. closed its underwritten public offering of 3,382,352 common shares at $34 apiece with gross proceeds of about $115 million.
The shares include the full exercise of the underwriters' option to buy an additional 441,176 shares.
JonesTrading Institutional Services LLC acted as sole book-running manager and Ladenburg Thalmann & Co. Inc. acted as joint book runner.
LifeSci Capital LLC acted as lead manager and B. Riley FBR Inc. acted as co-manager of the offering.